Global schizophrenia prevalence, companies analysis & drugs forecast (2010 – 2015)


Published on

Renub Research has announced the addition of "Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 – 2015)" to its offering.

For more details Please copy and paste the given link in browser: (

Contact Us
Ankit Mishra
Relationship Manager
Sales & Marketing Div
Renub Research
Phone: +1-678-302-0700 (USA) +91-120-254-5750 (India)

Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have long-term experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others.

Published in: Business, Health & Medicine
1 Like
  • Be the first to comment

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Global schizophrenia prevalence, companies analysis & drugs forecast (2010 – 2015)

  1. 1. Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast Renub Research Publisher: Renub Research Published: August, 2011
  2. 2. © Renub Research Page 2 of 8 Schizophrenia - Market Overview Schizophrenia is a mental disorder characterized by disintegration of thought processes and of emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, or lack of concentration and motivation and it is accompanied by significant social or occupational dysfunction. However with proper medication this disease can be contained to a great extent and Schizophrenia patients can lead a normal healthy life style. At present lot of drugs for Schizophrenia are available in the market. From the introduction of Clozapine in 1991.Since, 1960, the first atypical antipsychotic to treat schizophrenia, the growth of this class has been rapid. Zyprexa, Seroquel, Risperdal, Abilify, Geodon are the blockbuster drug which has changed the dynamics of the schizophrenia market. But the major worry for the manufactures of these drugs is that by 2011 and 2012 almost all the major blockbuster drugs are going off-patent. However, depot formulation is the emerging segment which has long term chances of success. The pipeline drug like Lurasidone, Staccato, Cariprazine, Pimavanserin have the comparable efficacy and a similar mechanism of action to that of the existing brands which will enter the market by 2011. Report Details “Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 – 2015)” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally and features latest available data covering:  Global Schizophrenia Market has been covered from 2004-2019  Global Schizophrenia patients in 7 countries  Top 10 Schizophrenia Drug Brands (Zyprexa, Seroquel, Risperdal, Abilify, Geodon, Lonasen, Serdolect, Invega, Fanapt, Saphris) data analysis of Past, Present and Future Market
  3. 3. © Renub Research Page 3 of 8  Top 3 Schizophrenia Depot Formulations Brands (Risperdal Consta, Invega Sustenna, Relprevv) data analysis of Past, Present and Future Market  Pipeline Developmental Agents (Lurasidone, Staccato, Cariprazine, Pimavanserin) Future Trends Analyis  Key Companies Strengths and Weakness analysis in Global Schizophrenia Research Highlights  The prevalence of Schizophrenia in United States is expected to reach nearly 4 Million by 2020  From 2012 onwards Schizophrenia market is expected to show a decline  Zyprexa is the most successful product in the history of neuroscience  Abilify hit blockbuster sales in 2006 and it is anticipated that sales will cross US$ 2.5 Billion by 2014.  Risperdal Consta is the blockbuster injectable form of medicines and predicted that the sale will cross US$ 2 Billion by 2014  Lurasidone, Staccato, Cariprazine, Pimavanserin are the pipepline drug which will be launched by 2011 Key Companies Analyzed This section covers the business description, Strengths and Weakness of major players in Global Schizophrenia Market. The key players analyzed in this section are – Eli Lilly and Company, AstraZeneca, Johnson & Johnson, Bristol-Myers Squibb and Pfizer. Data Sources Information and data in this report has been collected from various printable and non- printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations.
  4. 4. © Renub Research Page 4 of 8 Table of Contents 1. Executive Summary 2. Global Schizophrenia Market Past, Present & Future Trend 3. Prevalence of Schizophrenia in Top 7 Countries 3.1 United States of America 3.1.1 Schizophrenia Population & Future Scenario 3.2 Japan 3.2.1 Schizophrenia Population & Future Scenario 3.3 Germany 3.3.1 Schizophrenia Population & Future Scenario 3.4 France 3.4.1 Schizophrenia Population & Future Scenario 3.5 Italy 3.5.1 Schizophrenia Population & Future Scenario 3.6 United Kingdom 3.6.1 Schizophrenia Population & Future Scenario 3.7 Spain 3.7.1 Schizophrenia Population & Future Scenario 4. Global – Top 10 Schizophrenia Drug Brands Market Performance 4.1 Zyprexa (Olanzapine) 4.2 Seroquel (Quetiapine) 4.3 Geodon 4.4 Risperdal (Risperidone) 4.5 Lonasen 4.6 Serdolect 4.7 Abilify (Aripiprazole) 4.8 Invega (Paliperidone) 4.9 Fanapt (iloperidone) 4.10 Saphris (Asenapine)
  5. 5. © Renub Research Page 5 of 8 5. Global – Top 3 Schizophrenia Depot Formulations Brand Market Performance 5.1 Risperdal Consta (Risperidone) 5.2 Invega Sustenna (Paliperidone Palmitate) 5.3 Relprevv/Zyphdera (Olanzapine LAI) 6. Pipeline Developmental Agents – Future Trends 6.1 Lurasidone 6.2 Staccato (Loxapine Inhalation) 6.3 Cariprazine (RGH-188) 6.4 Pimavanserin 7. Key Companies 7.1 Eli Lilly and Company 7.1.1 Business Description 7.1.2 Strength & Weaknesses 7.2 Astrazeneca 7.2.1 Business Description 7.2.2 Strength & Weaknesses 7.3 Johnson & Johnson 7.3.1 Business Description 7.3.2 Strength & Weaknesses 7.4 Bristol-Myers Squibb 7.4.1 Business Description 7.4.2 Strength & Weaknesses 7.5 Pfizer 7.5.1 Business Description 7.5.2 Strength & Weaknesses
  6. 6. © Renub Research Page 6 of 8 Order Form Scan and e-mail this page to, alternatively one can also write the Contact Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780 Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to Format Report Title: Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 – 2015) Single User (Email from Publisher) Hard Copy (Mail Delivery) CD – Rom (Mail Delivery) Global Site License (Multiple User License) US$ 850 US$ 950 US$ 950 US$ 1,400 For ordering this report: Three easy ways to place your order: 1) Order online by Credit Card (Visa, MasterCard, etc.): forecast-2010---2015-47 2) Order by Wire Transfer: To pay by Wire Transfer, please, fill in your contact details in the form below:
  7. 7. © Renub Research Page 7 of 8 Bank Details Account Name: Renub Research A/C No.: 109102000023296 Name of Bank: IDBI Bank Ltd. Swift Code: IBKLINBB010 Bank Address: 4th Floor Indian Red Cross Building 1 Red Cross Road Opposite Parliament Street New Delhi – 110001 India Contact Information First Name: Last Name: Email: Job Title: Company: Address: City: Postal/Zip Code: Country: Phone: Mobile: Fax: Report Format: Your message:
  8. 8. © Renub Research Page 8 of 8 3) Order by Check Please post the check accompanied by this form, to: Company Address: Renub Research 1st Floor C-86, Sector -10 Noida - 201301 Uttar Pradesh India Phone: +91-120-421-9822, 424-9780 For free Sample copy report or to view any of our sample work please contact us at or call +91-120-421-9822 (India), +1-678-302-0700 (USA) Follow Us Facebook: LinkedIn: Twitter: